Soon Tjin Lim
Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis
Lim, Soon Tjin; Thijs, Vincent; Murphy, Stephen J. X.; Fernandez-Cadenas, Israel; Montaner, Joan; Offiah, Chika; Marquardt, Lars; Kelly, Peter J.; Bath, Philip M.; Lim, Su-Yin; Ford, Gary A.; Norrving, Bo; Cox, Dermot; Prodan, Calin I.; Barber, Philip A.; Werring, David J.; Perry, Richard; Zgaga, Lina; Dawson, Jesse; McCabe, Dominick J. H.
Stephen J. X. Murphy
Peter J. Kelly
PHILIP BATH firstname.lastname@example.org
Stroke Association Professor of Stroke Medicine
Gary A. Ford
Calin I. Prodan
Philip A. Barber
David J. Werring
Dominick J. H. McCabe
Background The prevalence of ex vivo ‘high on-treatment platelet reactivity (HTPR)’ and its relationship with recurrent vascular events/outcomes in patients with ischaemic cerebrovascular disease (CVD) is unclear.
Methods A systematic review and meta-analysis was performed in accordance with the PRISMA statement. MEDLINE, EMBASE and Cochrane Library were searched for completed manuscripts until May 2019 on TIA/ischaemic stroke patients, ≥ 18 years, treated with commonly-prescribed antiplatelet therapy, who had platelet function/reactivity testing and prospective follow-up data on recurrent stroke/TIA, myocardial infarction, vascular death or other cerebrovascular outcomes. Data were pooled using random-effects meta-analysis. Primary outcome was the composite risk of recurrent stroke/TIA, myocardial infarction or vascular death. Secondary outcomes were recurrent stroke/TIA, severe stroke (NIHSS > 16) or disability/impairment (modified Rankin scale ≥ 3) during follow-up.
Results Antiplatelet–HTPR prevalence was 3–65% with aspirin, 8–56% with clopidogrel and 1.8–35% with aspirin–clopidogrel therapy. Twenty studies (4989 patients) were included in our meta-analysis. There was a higher risk of the composite primary outcome (OR 2.93, 95% CI 1.90–4.51) and recurrent ischaemic stroke/TIA (OR 2.43, 95% CI 1.51–3.91) in patients with vs. those without ‘antiplatelet–HTPR’ on any antiplatelet regimen. These risks were also more than twofold higher in patients with vs. those without ‘aspirin–HTPR’ and ‘dual antiplatelet–HTPR’, respectively. Clopidogrel–HTPR status did not significantly predict outcomes, but the number of eligible studies was small. The risk of severe stroke was higher in those with vs. without antiplatelet–HTPR (OR 2.65, 95% CI 1.00–7.01).
Discussion Antiplatelet–HTPR may predict risks of recurrent vascular events/outcomes in CVD patients. Given the heterogeneity between studies, further prospective, multi-centre studies are warranted.
Lim, S. T., Thijs, V., Murphy, S. J. X., Fernandez-Cadenas, I., Montaner, J., Offiah, C., …McCabe, D. J. H. (2020). Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis. Journal of Neurology, https://doi.org/10.1007/s00415-020-09932-y
|Journal Article Type||Article|
|Acceptance Date||May 19, 2020|
|Online Publication Date||Jun 9, 2020|
|Publication Date||Jun 9, 2020|
|Deposit Date||Jun 12, 2020|
|Publicly Available Date||Jun 10, 2021|
|Journal||Journal of Neurology|
|Peer Reviewed||Peer Reviewed|
|Keywords||Platelet function/on-treatment platelet reactivity, Transient ischaemic attack, Ischaemic stroke, Systematic review, Meta-analysis|
|Additional Information||This is a post-peer-review, pre-copyedit version of an article published in Journal of Neurology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00415-020-09932-y|
Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: Systematic review and meta-analysis